Emergency Medicine Cases – Where the Experts Keep You in the Know. For complete episodes please visit emergencymedicinecases.com
Manish A. Shah, MD, FASCO - Checkpoint Inhibition in Gastrointestinal Cancers: Recent Advances in Gastric, Esophageal, and Colorectal Cancers and Their Application in Clinical Practice
Manage episode 286008048 series 103583
著作 PeerView, 24 West 40th Street, Suite 950, New York, NY 10018, PVI, and PeerView Institute for Medical Education の情報はPlayer FM及びコミュニティによって発見されました。著作権は出版社によって所持されます。そして、番組のオーディオは、その出版社のサーバから直接にストリーミングされます。Player FMで購読ボタンをタップし、更新できて、または他のポッドキャストアプリにフィードのURLを貼り付けます。
Go online to PeerView.com/UFG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In recent years, immune checkpoint inhibitors have demonstrated superior benefits in a spectrum of GI malignancies, including colorectal, esophageal, and gastric cancers. In this educational activity, experts will present a MasterClass featuring in-depth analysis of the latest evidence on the present and future use of checkpoint inhibitors in the management of GI cancers, along with practical guidance on incorporating these agents into clinical practice. Upon completion of this activity, participants should be better able to: Summarize the rationale for use of checkpoint inhibitors, including when testing for PD-L1, MMR/MSI status, and other predictors of response is needed, across the spectrum of GI cancers, Appraise the latest safety and efficacy evidence on available dual and single agent checkpoint inhibition strategies for patients with advanced GI cancers, including gastric, esophageal, GEJ, and colorectal cancers, Review emerging data regarding the use of checkpoint inhibitors in combination regimens and in early treatment settings, including first-line and perioperative settings, for patients with GI cancers, Develop safe and effective treatment plans incorporating immune checkpoint inhibitors, including enrollment within clinical trials, for eligible patients with advanced and earlier-stage GI cancers.